Immune senescence and vaccines to prevent herpes zoster in older persons
- PMID: 22857823
- DOI: 10.1016/j.coi.2012.06.002
Immune senescence and vaccines to prevent herpes zoster in older persons
Abstract
Varicella-zoster virus (VZV) T-cell-mediated immunity (VZV-CMI) in older persons prevents latent VZV in sensory neurons from reactivating to cause herpes zoster. VZV-CMI declines greatly with aging, but can be restored by the licensed zoster vaccine. However, the vaccine-induced boost in VZV-CMI (which determines the efficacy of the vaccine) is a function of the age of the vaccinee, and the duration of this boost wanes with time. Both factors influence the value of this vaccine. To understand these aging effects, limited information about the phenotypic and functional differences in VZV-CMI in old and young persons are reviewed, as well as the reversal of these differences by vaccination. Based on information from these studies some potential approaches to improving prevention of herpes zoster are discussed.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Zoster vaccine: current status and future prospects.Clin Infect Dis. 2010 Jul 15;51(2):197-213. doi: 10.1086/653605. Clin Infect Dis. 2010. PMID: 20550454 Review.
-
The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.J Virol. 2019 Jul 17;93(15):e00305-19. doi: 10.1128/JVI.00305-19. Print 2019 Aug 1. J Virol. 2019. PMID: 31092579 Free PMC article.
-
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.J Infect Dis. 2008 Mar 15;197(6):825-35. doi: 10.1086/528696. J Infect Dis. 2008. PMID: 18419349 Free PMC article. Clinical Trial.
-
Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.J Infect Dis. 2016 Jan 1;213(1):14-22. doi: 10.1093/infdis/jiv480. Epub 2015 Oct 9. J Infect Dis. 2016. PMID: 26452397 Clinical Trial.
-
Varicella zoster virus vaccines: effective, but concerns linger.Can J Ophthalmol. 2009 Aug;44(4):379-84. doi: 10.3129/i09-126. Can J Ophthalmol. 2009. PMID: 19606157 Review.
Cited by
-
Comparison of the efficacy of continuous epidural block with epidural electrical stimulation and conventional continuous epidural block for management of zoster-associated pain beyond the acute phase: A retrospective study.Medicine (Baltimore). 2019 Sep;98(39):e17026. doi: 10.1097/MD.0000000000017026. Medicine (Baltimore). 2019. PMID: 31574800 Free PMC article.
-
Ageing and myeloid-derived suppressor cells: possible involvement in immunosenescence and age-related disease.Age (Dordr). 2014;36(6):9729. doi: 10.1007/s11357-014-9729-x. Epub 2014 Nov 16. Age (Dordr). 2014. PMID: 25399072 Free PMC article. Review.
-
Varicella-zoster virus proteome-wide T-cell screening demonstrates low prevalence of virus-specific CD8 T-cells in latently infected human trigeminal ganglia.J Neuroinflammation. 2023 Jun 12;20(1):141. doi: 10.1186/s12974-023-02820-y. J Neuroinflammation. 2023. PMID: 37308917 Free PMC article.
-
Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years.Drugs. 2013 Jul;73(11):1227-44. doi: 10.1007/s40265-013-0088-1. Drugs. 2013. PMID: 23839657 Review.
-
Persistence of Varicella-Zoster Virus-Specific Plasma Cells in Adult Human Bone Marrow following Childhood Vaccination.J Virol. 2020 Jun 16;94(13):e02127-19. doi: 10.1128/JVI.02127-19. Print 2020 Jun 16. J Virol. 2020. PMID: 32321817 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
